BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20093977)

  • 1. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
    Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
    J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.
    Gately K; Al-Alao B; T Dhillon ; Mauri F; Cuffe S; Seckl M; O'Byrne K
    Lung Cancer; 2012 Feb; 75(2):217-22. PubMed ID: 21802763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
    Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
    J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
    Urban D; Bar J; Solomon B; Ball D
    J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.
    Higgins KA; Chino JP; Ready N; D'Amico TA; Berry MF; Sporn T; Boyd J; Kelsey CR
    J Thorac Oncol; 2012 Jul; 7(7):1141-7. PubMed ID: 22617241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of IGF1R expression in non-small-cell lung cancer.
    Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
    Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
    Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
    J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
    Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
    Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
    World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
    Qiu C; Dong W; Su B; Liu Q; Du J
    J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
    Gottlin EB; Bentley RC; Campa MJ; Pisetsky DS; Herndon JE; Patz EF
    J Thorac Oncol; 2011 Oct; 6(10):1687-90. PubMed ID: 21642860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer.
    Zhang Y; Ni HJ; Cheng DY
    Asian Pac J Cancer Prev; 2013; 14(6):3725-8. PubMed ID: 23886172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.